We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Argentum Wins Invalidation of J&J Unit’s Cancer Drug Patent

Law360, Los Angeles (January 17, 2018, 11:07 PM EST) -- The U.S. Patent Trial and Appeal Board ruled Wednesday that a patent for Johnson & Johnson’s Zytiga prostate cancer drug described an obvious process, invalidating the last remaining patent blocking Argentum...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.